UK Review Seeks Sea Change In Drug Development
This article was originally published in SRA
Executive Summary
The UK government's accelerated access review project is planning to bring big and meaningful changes to the way drugs are developed and brought to UK patients and is not just a tweak to the system1,2, says, Stuart Dollow, chief executive and founder of Vermilion Life Sciences, who is helping to lead the review.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.